APAD

APAD Biotherapeutics is a German biotechnology company focused on developing novel immunotherapies for neurodegenerative diseases. The company's primary approach involves targeting the ASC protein (apoptosis-associated speck-like protein containing a CARD), which plays a central role in the formation of inflammasomes and the propagation of neuroinflammation. By utilizing proprietary monoclonal antibodies to neutralize extracellular ASC specks, APAD aims to halt the progression of diseases such as Alzheimer's and Parkinson's. Their research is built on the understanding that ASC specks act as prions, spreading inflammation throughout the brain. APAD is currently advancing its lead antibody candidates through pre-clinical development to address significant unmet needs in neurology.